Business
NAYA Biosciences Announces Development of NY-500, a Novel AI-Optimized PD-1 x VEGF Bifunctional Antibody
• PD-1 x VEGF antibodies show potential to surpass checkpoint inhibitors as standard-of-care in multiple oncology indications • NAYA aiming to initiate
About this update from Invo Fertility, Inc.
[{"type":"text","content":"• PD-1 x VEGF antibodies show potential to surpass checkpoint inhibitors as standard-of-care in multiple oncology indications • NAYA aiming to initiate clinical trials in early 2026 SARASOTA, Fla. and MIAMI, Jan. 06, 2025 (GLOBE NEWSWIRE) -- NAYA Biosciences (“NAYA”) (NASDAQ: NAYA), a life science portfolio company dedicated to bringing breakthrough treatments to patients in oncology, autoimmune diseases, and women’s health, today announced that it is expanding its bifunctional antibody pipeline to include a novel PD-1 x VEGF tetravalent bifunctional antibody for the treatment of hepatocellular carcinoma (HCC) and other solid tumors. NAYA is leveraging its proprietary FLEX antibody platform and further optimizing its design through a partnership with MabSilico, an artificial intelligence & deep technology-focused company, to accelerate the development of new best-in-class candidates for validated therapeutic targets. “We are excited to add a novel, AI-optimized PD-1 x VEGF therapeutic candidate to our pipeline of best-in-class bifunctional antibodies,” commented NAYA Biosciences President Dr. Daniel Teper. “NAYA’s bifunctional format has demonstrated the ability for synergistic dual-targeting activity, resulting in the potential to unlock clinical response in solid tumors. NY-500, our PD-1 x VEGF antibody, will target hepatocellular carcinoma (HCC) and other solid tumors with high unmet medical needs. Recent clinical data with ivonescimab, the most advanced PD-1 x VEGF antibody, has shown superiority in non-small-cell lung cancer (NSCLC) compared to Keytruda®, the leading first-line immunotherapy standard-of-care in multiple solid tumors, paving the way for a new generation of PD-(L)1 therapeutic candidates.” NAYA is also developing a GPC3-targeting bifunctional antibody (NY-303) in a phase 1/2 clinical trial for HCC patients not responding to PD-1 +/- VEGF therapy. NAYA has recently presented data for NY-303 at the Society for Immunotherapy of Cancer (SITC) demonstrating the ability to reverse resistance to PD-1 checkpoint blockage and turn tumors from a “cold” into a “hot” status, making the tumors susceptible to immunotherapy again. Initiation of monotherapy Phase 1/2a clinical trials has been cleared by regulatory authorities and leading academic centers and is expected to start in 2025. About NY-500 (PD-1 x VEGF Bifunctiona...